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The aim was to define a multifunctional evaluation protocol 
in patients with Mc Ardle’s disease in order to detect and quan-
tify the impairment of both muscular energetic metabolism and 
motor performance. The protocol has been used to investigate 
the effect of a carbohydrate-rich diet integrated with tricarboxy-
lic acid cycle intermediate and creatine on exercise intolerance 
and motor skills in these patients.
We studied 4 patients with complete myophosphorylase 
deficiency, 1 paucisymptomatic patient with partial myophos-
phorylase deficiency and 5 sex- and age-matched healty sub-
jects, who have been evaluated by: 1) monitoring of physical 
activity with an electronic armband; 2) testing of cardiopul-
monary, metabolic and respiratory responses to exercise with 
a cardiopulmonary exercise test (CPET) in wich subjects were 
asked to pedal on a bicycle ergometer, using a costant workload 
for 12 minutes followed by an incremental workload to exhaus-
tion; 3) examination of oxidative stress biomarkers (AOPP and 
thiols) at rest and during exercise.
The same measurements were then repeated by the patients 
after three days of carbohydrate-rich diet (20% fat, 15% protein 
and 64% carbohydrate) integrated with tricarboxylic acid cycle 
intermediate and creatine.
The monitoring with armband showed that low levels of 
physical activity are prominent in patients with Mc Ardle’s dis-
ease. During the costant workload exercise on the bicycle er-
gometer 3 patients experienced the characteristic “second wind”, 
whereas in the patient with partial myophosphorylase deficiency 
(patient carrier) heart rate increased progressively, as in all the 
healty subjects. Heart rate was consistently lower in healty sub-
jects then in patients, indicating that they were performing at a 
higher percentage of their exercise reserve. Maximal oxygen up-
take was significantly lower in patients (p < 0.05), showing how 
Mc Ardle’s disease has a significant effect on the maximal oxida-
tive capacity. The sampling of oxidative stress biomarkers (AOPP 
and thiols) blood levels showed lower levels of AOPP and higher 
levels of thiols in patients than in healty subjects.
We did not observe significant differences between baseline and 
the results obtained after three days of carbohydrate-rich diet inte-
grated with tricarboxylic acid cycle intermediate and creatine.
The protocol has confirmed the impairment of both anaero-
bic and oxidative metabolism in skeletal muscle. The sensitivity 
of the test allowed to appreciate the “second wind” phenomenon 
and to detect the case of the carrier patient, who had intermedi-
ate phenotypic characteristics between patients and healty sub-
jects; by the way the test could be useful to obtain an objective, 
quantitative and longitudinal evaluation of the impairment to be 
used in the follow-up of patients with Mc Ardle’s disease as well 
as in the assessment of therapeutic interventions.
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Myasthenia  gravis  (MG)  is  an  autoimmune  disorder,  in 
90%  of  cases  antibodies  against  the  nicotinic  acetylcholine 
receptor (AchRAb) are pathogenetic. Antibodies reduce ace-
tylcholine receptors (AChR) number and impair their function 
at the neuromuscular endplate. The main feature is a variable 
weakness of the skeletal muscles, that may involve different 
districts. Symptoms are typically worse in the evening or after 
prolonged exercise and can be reduced with rest. The diagnosis 
is based on a detailed clinical history and neuromuscular exami-
nation, on pharmacological tests, measurement of AchRAb, and 
on appropriate neurophysiologic tests. Therapy involves the use 
of symptomatic drugs that can improve neuromuscular trans-
mission,  immunosuppressive  and  immunomodulant  therapy, 
and thymectomy.
The task of our study was to compare the efficacy of differ-
ent immunosuppressive regimens in patients with MG.
We carried out a study in 98 patients at the Clinical Cen-
tre for Neuromuscular diseases of Padova University: 36 were 
treated by combined immunotherapy with corticosteroids and 
Azathioprine (CS and AZA), 13 of them treated with a com-
bination of corticosteroids and Cyclosporine (CS and CsA), 
and a third group of 49 patients in treatment with only corti-
costeroids (CS). We also report a follow-up study of 5 patients 
treated with Mycophenolate mofetil (MMT). All patients were 
evaluated using the MGFA (Myasthenia Gravis Foundation of 
America)  clinical  classification.  Appropriate  statistics  have 
been  performed,  with  multivariate  analysis  and  Student  T 
tests.
To evaluate the outcome of the 98 patients of the study, we 
considered the difference between patients with a MGFA score 
equal  to  zero  (patients  asymptomatic  or  in  pharmacological 
remission) and patients with MGFA score different from zero 
(symptomatic, with various grades of severity). After one year 
of treatment the percentage of pharmacological remissions or 
asymptomatic status in the group of patients treated with AZA 
and CS resulted greater than in the group of patients treated 
with only corticosteroids or both with CsA and CS. Side effects 
resulted significantly (p < 0.0001) common in the groups of 
patients treated with the therapeutical combination of immuno-
suppressors, than in the group treated just with steroids. Three 
out of 5 patients treated with MMT achieved an improvement 
within the first year of treatment.
Combined therapy with immunosuppressive agents and 
corticosteroids, significantly increases the number and fre-
quency of side effects (p < 0.0001). Our findings also reveal 
that Cushing’s syndrome and osteoporosis were significantly 
common among patients treated only with steroids (p < 0.003 
and p < 0.03). Additional studies are required to confirm the 
role of Mycophenolate Mofetil in the treatment of Myasthenia 
Gravis.